RT Journal Article
SR Electronic
T1 Quantifying phenotype and genotype distributions in single muscle fibres from patients carrying the pathogenic mtDNA variant m.3243A>G
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.04.22272484
DO 10.1101/2022.04.04.22272484
A1 Ahmed, Syeda T
A1 Taylor, Robert W
A1 Turnbull, Doug M
A1 Lawless, Conor
A1 Pickett, Sarah J
YR 2022
UL http://medrxiv.org/content/early/2022/04/22/2022.04.04.22272484.abstract
AB Background Pathogenic mitochondrial (mt)DNA variants cause neuromuscular disease with highly variable severity and phenotypic presentation, the reason for which is poorly understood. Cells are thought to tolerate the presence of pathogenic mtDNA variants up to a threshold proportion with little or no functional consequence, developing significant respiratory complex defects above this threshold. We developed a robust method to identify deficient muscle fibres, applied it to biopsies from 17 patients carrying the common m.3243A>G variant and examined the relationship between respiratory deficiency and m.3243A>G level in hundreds of single skeletal muscle fibres. We hypothesised that single-cell between-patient differences may explain the vast clinical heterogeneity of mtDNA disease.Results Immunohistochemical measurements of respiratory complexes I and IV and unsupervised machine learning identified muscle fibres with respiratory deficiency; the pattern of deficiency and proportion of deficient fibres (range 0-64%) varies between patients. Tissue homogenate m.3243A>G level is a poor surrogate for the broad and complex distributions of m.3243A>G level in single cells from individual patients. Estimated thresholds do not differ between patients, but sections with narrow m.3243A>G distributions have a lower proportion of deficient fibres.Conclusions Inter-individual differences in respiratory complex deficiency in muscle fibres from patients with m.3243A>G are more complex than previously thought and may be driven by differential segregation and expansion of mtDNA molecules. Our quantitative observations could constrain the range of feasible mechanisms responsible for phenotypic diversity in mitochondrial disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was also supported by a Wellcome Career Re-entry Fellowship to S.J.P. (204709/Z/16/Z); the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1); the UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust; the Lily Foundation; the Pathological Society; and the UK NHS Specialist Commissioners which funds the "Rare Mitochondrial Disorders of Adults and Children" Diagnostic Service in Newcastle upon Tyne. Funding for open access charge: Charity open access fund (COAF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mitochondrial disease patient tissue and ethical approval was provided by the Newcastle Mitochondrial Research Biobank (REC reference 16/NE/0267-Application Ref: MRBOC ID 016), supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z) and UK NHS Highly Specialised Service for Rare Mitochondrial Disorders. Data for the study were obtained from the Wellcome Centre for Mitochondrial Research Patient Cohort (MitoCohort) (REC Ref: 13/NE/0326-Application Ref: MDOC ID 049).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at: https://github.com/lwlss/mito_muscle_sections and https://dx.doi.org/10.25405/data.ncl.19416005